KLRK1 and glioblastoma: As for the (CAR)-T therapy of GBM (adoptive cell transfer of ex vivo expanded and transformed T cells), several surface markers of GBM are currently being used for development of CAR proteins, namely NKG2D [129], EGFRvIII [130], IL13Rα2 [131], HER2 [132], GD2 [133], etc. Results of corresponding clinical trials are comprehensively reviewed elsewhere [134].